Pharmacokinetic and pharmacodynamic modeling of cibenzoline plasma concentrations and antiarrhythmic effect.
The plasma concentration and antiarrhythmic effect data following multiple, ascending oral doses of cibenzoline in four patients with frequent premature ventricular contractions (PVCs) were analyzed using pharmacokinetic and pharmacodynamic modeling. Three methods of data analysis were tested in the analysis of the large amount of arrhythmia frequency data gathered during the study: as total-data set, average-data set, and grouped-data set. We have shown that the antiarrhythmic effect profile of the drug could be characterized by average data when a large number of PVC measurements are involved. Using the average-data sets, the plasma concentration of the drug at steady state could be correlated to the antiarrhythmic response using pharmacokinetic and pharmacodynamic modeling.
A A
AA
Holazo
R K
RK
Brazzell
W A
WA
Colburn
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000097:blood; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004341:Drug Evaluation; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000097:blood / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D008433:Mathematics; D008875:Middle Aged; D008954:Models, Biological; D009200:Myocardial Contraction / Q000187:drug effects; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D007093:Imidazoles; C032151:cifenline